Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FlyteHealth vs Next Vial

FlyteHealth
Graded #364

Lower grade

vs+0.6999999999999957
Next Vial
Graded #345

Higher grade

The verdict

Next Vial takes it — 59.3/100 to 58.6/100, but only just.

Next Vial grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Fully online GLP-1 telehealth marketplace connecting patients with licensed providers for compounded semaglutide and tirzepatide injections, including microdose options. FlyteHealth is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFlyteHealth +5
45
40
Dose & formulationNext Vial +12
40
52
Clinical oversightFlyteHealth +1
83
82
Labs & monitoringFlyteHealth +21
73
52
FulfillmentNext Vial +24
62
86
Contract termsEven
55
55
FlyteHealth · left barNext Vial · right bar

The numbers

MetricFlyteHealthNext Vial
WeighScore58.6/10059.3/100
GradeCC
Scorecard rank#364#345
SemaglutideNot disclosed$250/mo (compounded)
TirzepatideNot disclosedNot disclosed
CoverageCoverage not published49 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
FlyteHealth

Graded #364 · C

Strengths

  • Care led by board-certified obesity-medicine physicians
  • Multidisciplinary team with NPs, dietitians, and care coordinators
  • Published outcomes of about 13 to 16 percent weight loss over 12 months
  • High GLP-1 medication adherence (around 86 percent in reported data)
  • Comprehensive cardiometabolic care beyond GLP-1 alone

Where it loses points

  • Distributed primarily via employers, payers, and health plans, not direct cash-pay
  • Access is largely gated behind employer or plan sponsorship
  • GLP-1 is prescribed only when appropriate, not guaranteed
  • Self-pay pricing is not publicly listed (contact required)
  • Less suited to consumers wanting fast direct-to-door GLP-1
Next Vial

Graded #345 · C

Strengths

  • LegitScript verified with named pharmacy partner (Manifest Pharmacy, Greer, SC)
  • No membership fees — one all-in price covering consultation, medication, and shipping
  • Compounded semaglutide, tirzepatide, and microdose options available
  • Free rushed shipping; serves 49 states nationwide
  • Board-certified physician oversight with ongoing provider support

Where it loses points

  • Tirzepatide pricing not listed publicly (starting price covers GLP-1 generally)
  • Compounded medications are not FDA-approved
  • Labs and nutritional coaching not disclosed
  • Microdose pricing not published on product page
  • Alaska not listed among served states

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard